Company Filing History:
Years Active: 2024
Title: John Michael Gansner: Innovator in RNAi Technology
Introduction
John Michael Gansner is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) technologies. His work focuses on addressing disorders associated with the TMPRSS6 gene, which plays a crucial role in iron metabolism.
Latest Patents
Gansner holds a patent for "Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof." This invention relates to RNAi agents, specifically double-stranded RNA (dsRNA) agents, that target the TMPRSS6 gene. The patent outlines methods for using these RNAi agents to inhibit the expression of the TMPRSS6 gene. This innovation has potential applications in preventing and treating various disorders, including hereditary hemochromatosis, β-thalassemia, and neurodegenerative diseases such as Parkinson's and Alzheimer's.
Career Highlights
Gansner is currently associated with Alnylam Pharmaceuticals, Inc., a leading company in the field of RNAi therapeutics. His work at Alnylam has positioned him at the forefront of innovative treatments that leverage RNAi technology to address complex medical conditions.
Collaborations
Throughout his career, Gansner has collaborated with esteemed colleagues, including Aimee M Deaton and James D McIninch. These collaborations have further enhanced the development and application of RNAi technologies in therapeutic settings.
Conclusion
John Michael Gansner's contributions to RNAi technology and his innovative patent on TMPRSS6 iRNA compositions highlight his role as a key figure in biotechnology. His work continues to pave the way for advancements in the treatment of iron overload disorders and other related conditions.